Abstract：Objective To explore the correlation between platelet antibodies,cross matching results,and ineffective platelet transfusion in patients with multiple myeloma.Method A retrospective analysis was conducted on 124 patients with multiple myeloma.The patients were divided into an effective group and an ineffective group based on whether platelet transfusion was effective.Among them,there were 100 cases in the effective group and 24 cases in the ineffective group.Compare the clinical data,platelet antibodies,and cross matching results of two groups of patients,and analyze the correlation between platelet antibodies,cross matching results,and ineffective platelet transfusion in patients with multiple myeloma,as well as the influencing factors of ineffective platelet transfusion.Result Factor analysis showed that splenomegaly（β=3.524,...）,OR=3.933,95%Cl=7.047-13.397）、 Heat generation（β=1.630,OR=5.102,95%Cl=1.389-18.744）、 Platelet antibody positivity（β=2.114,OR=8.280,95% Cl=2.056-23.340）and cross matching positivity（β=1.548,OR=4.701,95% Cl=1.104-20.016）are both influencing factors for ineffective platelet transfusion in patients.Conclusion Positive platelet antibodies,cross matching,fever,and splenomegaly are independent influencing factors for ineffective platelet transfusion in patients with multiple myeloma.Clinical attention should be paid to patients with multiple myeloma who are accompanied by these influencing factors.
苏情, 傅丽霞, 巢玲. 血小板抗体、交叉配型与骨髓瘤输注无效相关性研究[J]. 哈尔滨医药, 2025, 45(2): 37-39.
Su Qing, Fu Lixia, Chao Ling. Study on the Correlation between Platelet Antibodies Cross Matching and Ineffectiveness of Myeloma Infusion. journal1, 2025, 45(2): 37-39.
[1] 冷瑞芳. 多发性骨髓瘤患者疾病不确定感水平及其相关影响因素分析[J].山西医药杂志,2023,52(14):1066-1068. [2] 胡文静,叶盛,费荣,等.血液病患者预防性血小板输注的研究进展[J].临床血液学杂志,2016,29(01):86-88. [3] 王慧茹,刘会兰.血小板输注无效临床诊疗困境[J].安徽医学,2023,44(08):883-886. [4] Lani L,Yang L,Carol P,et al.An epidemiologic cohort study reviewing the practice of blood product transfusions among a population of pediatric oncology patients.[J].Transfusion,2014,54. [5] Phuong V,Enkhtsetseg P,A K W,et al.A pilot trial of complement inhibition using eculizumab to overcome platelet transfusion refractoriness in human leukocyte antigen allo-immunized patients[J].British journal of haematology,2020,189(3). [6] 冯文芳. 临床血小板输注无效的影响原因分析[J].婚育与健康,2023,29(03):91-93. [7] 高永祥,张晋昕.Logistic回归分析的样本量确定[J].循证医学,2018,18(02):122-124. [8] S A A,P M C,A N F,et al.Antibodies to human platelet antigens form a significant proportion of platelet anti-bodies detected in Indian patients with refractoriness to platelet transfusions[J].Transfusion medicine(Oxford,England),2018,28(5). [9] Duquesnoy R,Marrari M,Marroquim M,et al.Second update of the International Registry of HLA Epitopes I.The HLA-ABC epitope database[J].Human Immuno-logy,2018,80(2). [10] Ahmadi A,Khansarinejad B,Hosseinkhani S,et al.miR-199a-5p and miR-495 target GRP78 within UPR pathway of lung cancer[J].Gene,2017,620. [11] 刘娜,王洁,李冬妹,等.血小板抗体检测及交叉配型结果分析[J].北京医学,2022,44(08):743-745. [12] ARNOLD D M,CROWTHER M A,COOK R J,et al.Utilization of platelet transfusions in the intensive care unit:indications,transfusion triggers,and platelet count responses[J].Transfusion,2006,46(8):1286-1291. [13] Lee H R,Kasthuri S R,Bergmeier W.Platelet transfusion for patients with platelet dysfunction:effectiveness,me-chanisms,and unanswered questions[J].Current opinion in hematology,2020. [14] 冯文芳. 临床血小板输注无效的影响原因分析[J].婚育与健康,2023,29(03):91-93. [15] 苏高繁,陈静思,郑婷婷,等.血小板输注无效列线图预测模型的构建[J].温州医科大学学报,2021,51(09):741-745. [16] 黎敏,姜伟,杜慧,等.单采血小板输注疗效列线图预测模型的构建与评估[J].中国输血杂志,2021,34(06):613-616.
2025, Vol. 45 
